NON RARE IN EUROPE: Adenocarcinoma of stomach

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

45Recruiting trials

Regulatory Watchboard

10 events

Apr 2026QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd. — PHASE1, PHASE2

TrialNOT YET RECRUITING

Feb 2026Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca — PHASE3

TrialRECRUITING

Feb 2026Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer

Blokhin's Russian Cancer Research Center

TrialACTIVE NOT RECRUITING

Feb 2026A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

Dong-A ST Co., Ltd. — PHASE1

TrialNOT YET RECRUITING

Jan 2026Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study

Shanghai Zhongshan Hospital — PHASE2

TrialNOT YET RECRUITING

Jan 2026EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Eikon Therapeutics — PHASE1, PHASE2

TrialRECRUITING

Dec 2025Evaluation of the NEOmom® Gastric Video Capsule for Gastric Cancer Screening

Nantes University Hospital — NA

TrialNOT YET RECRUITING

Dec 2025AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)

Imperial College London

TrialNOT YET RECRUITING

Oct 2025Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Massachusetts General Hospital — PHASE2

TrialRECRUITING

Sep 2025Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Jiangsu HengRui Medicine Co., Ltd. — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for NON RARE IN EUROPE: Adenocarcinoma of stomach.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Vyloy

(zolbetuximab-clzb)Orphan drugstandard

Astellas Pharma Global Development Inc.

Claudin 18.2-directed Cytolytic Antibody [EPC]

12.1 Mechanism of Action Zolbetuximab-clzb is a claudin 18.2 (CLDN18.2)-directed cytolytic antibody that depletes CLDN18.2-positive cells via antibody...

View full treatment details on disease page →

Clinical Trial Landscape

45 active trials

2Phase 3

17Phase 2

8Phase 1

4N/A

8Unknown

5PHASE1, PHASE2

1PHASE2, PHASE3

45Total recruiting

Search clinical trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →

Recent News & Research

No recent news articles indexed yet for NON RARE IN EUROPE: Adenocarcinoma of stomach.
Search PubMed for NON RARE IN EUROPE: Adenocarcinoma of stomach →

Browse all NON RARE IN EUROPE: Adenocarcinoma of stomach news →

Specialist Network

No specialists currently listed for NON RARE IN EUROPE: Adenocarcinoma of stomach.

View all NON RARE IN EUROPE: Adenocarcinoma of stomach specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles